Physician profile
Jorge A Larranaga
NPI 1346215308
$825,071.12
in general payments reported to CMS, 2019-2025
41 companies · $161K in 2025
The $161K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,320 · 2020: $19K · 2021: $31K · 2022: $213K · 2023: $244K · 2024: $155K · 2025: $161K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $249K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $204K · Travel and Lodging: $87K · Food and Beverage: $17K · Consulting Fee: $3,322 · Education: $335 · Gift: $40.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $248,900.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $204,495.00 |
| Travel and Lodging | $86,860.79 |
| Food and Beverage | $16,546.23 |
| Consulting Fee | $3,322.02 |
| Education | $334.99 |
| Gift | $40.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $378,371.56 | 2022-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $230,594.97 | 2021-2025 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $112,700.15 | 2020-2025 | Acthar, Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $80,332.87 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $9,928.38 | 2019-2024 | Ultomiris |
| Astrazeneca Pharmaceuticals Lp | $4,301.17 | 2019-2025 | Farxiga, Lokelma |
| Horizon Therapeutics Plc | $2,494.78 | 2019-2023 | Krystexxa |
| Vifor Pharma, INC. | $846.03 | 2019-2025 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $644.94 | 2019-2025 | Jynarque |
| Novartis Pharmaceuticals Corporation | $528.94 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $486.09 | 2023-2025 | Jardiance |
| Opko Pharmaceuticals, LLC | $446.26 | 2019-2025 | Rayaldee |
| Travere Therapeutics, INC. | $388.47 | 2021-2025 | Filspari, Thiola |
| Amgen INC. | $339.51 | 2019-2025 | Tavneos, Aranesp, Parsabiv |
| Ani Pharmaceuticals, INC. | $307.65 | 2022-2024 | Purified Cortrophin Gel |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $296.72 | 2019-2024 | Renal - Pd |
| Akebia Therapeutics INC | $274.75 | 2019-2025 | Vafseo, Auryxia |
| Glaxosmithkline, LLC. | $255.71 | 2021-2025 | Benlysta, Jesduvroq, Nucala |
| Ardelyx, INC. | $250.08 | 2024-2025 | Ibsrela |
| Fresenius USA Marketing, INC. | $206.11 | 2021-2025 | Velphoro, Velphoro, Korsuva |
| Mallinckrodt Enterprises LLC | $205.11 | 2019 | |
| Vantive US Healthcare LLC | $115.95 | 2025 | Renal - Pd |
| Novo Nordisk INC | $95.64 | 2022-2025 | Ozempic |
| Coloplast Corp | $93.80 | 2025 | |
| Lilly USA, LLC | $68.02 | 2023-2025 | Jardiance |
| Scpharmaceuticals INC. | $59.47 | 2025 | |
| Boston Scientific Corporation | $55.55 | 2025 | Varithena Administration Pack |
| Takeda Pharmaceuticals U.S.A., INC. | $45.02 | 2020-2025 | Gattex |
| Nxstage Medical, INC. | $44.79 | 2019 | |
| Alnylam Pharmaceuticals INC. | $40.96 | 2022-2023 | Givlaari |
| Renalytix Ai, INC. | $37.87 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Ultragenyx Pharmaceutical INC. | $37.25 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $34.89 | 2025 | Voyxact |
| Biocompatibles, INC. | $24.48 | 2019 | |
| Xeris Pharmaceuticals, INC. | $21.95 | 2025 | Keveyis |
| Shire North American Group INC | $20.05 | 2019 | |
| Amicus Therapeutics, INC. | $18.90 | 2022 | |
| Kyowa Kirin, INC. | $18.35 | 2025 | |
| Cormedix INC. | $13.55 | 2025 | Defencath |
| Daiichi Sankyo INC. | $12.71 | 2019 | |
| Shield Therapeutics INC | $11.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Larranaga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.